Dr. Nathalie Ganne-Carrié: Exploration and Clinical Practice of Biomarkers for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor worldwide. Although the prognosis for HCC patients is generally poor, if diagnosed early, the 5-year survival rate can exceed 70%. Currently, the diagnosis of HCC without pathological evidence mainly relies on analyzing serum alpha-fetoprotein (AFP) levels and radiological diagnosis. Therefore, exploring early diagnostic biomarkers for HCC is of great clinical significance. In recent years, with advancements in genomics and proteomics, and the rapid development of biomarker detection technologies, numerous new biomarkers have been identified, promising to improve early diagnosis of HCC. At the recently concluded 17th annual meeting of the International Liver Cancer Association (ILCA), Dr. Nathalie Ganne-Carrié from the University Hospital of Paris Seine-Saint-Denis gave a special report on the progress of early diagnostic biomarkers for HCC. We invited Dr. Nathalie Ganne-Carrié for an in-depth interview. Here's a summary for our readers.